Top Markets
Coin of the day
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Rang in Aktien #14767
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Aktienkurs
$16.85
Zuletzt synchronisiert: 2023-07-07
Marktkapitalisierung
$393.50M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CH
Handel VectivBio Holding AG (VECT)

Kategorie

Kursverlauf für VectivBio Holding AG (VECT)
Höchster Schlusskurs: $16.72 am 2023-07-01

Niedrigster Schlusskurs: $16.68 am 2021-04-01
Kursverlauf der Aktie von VectivBio Holding AG von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 96.64%
2022 112.95%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$746.00 4.56%
CH